IMMUNOREACT 0: Biopsy-based immune biomarkers as predictors of response to neoadjuvant therapy for rectal cancer-A systematic review and meta-analysis.
lymphocytes
marker
neoadjuvant therapy
pathological complete response
rectal cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
03
07
2023
received:
25
02
2023
accepted:
26
07
2023
medline:
4
10
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
The main therapy for rectal cancer patients is neoadjuvant therapy (NT) followed by surgery. Immune biomarkers are emerging as potential predictors of the response to NT. We performed a meta-analysis to estimate their predictive significance. A systematic literature search of PubMed, Ovid MEDLINE and EMBASE databases was performed to identify eligible studies. Studies on patients with rectal cancer undergoing NT in which the predictive significance of at least one of the immunological markers of interest was assessed by immunohistochemistry (IHC) in pretreatment biopsies were included. Seventeen studies reporting sufficient data met the inclusion criteria for meta-analysis. High levels of total CD3+, CD4+ and CD8+ tumor infiltrating lymphocytes (TILs), as well as stromal and intraepithelial CD8+ compartments, significantly predicted good pathological response to NT. Moreover, high levels of total (tumoral and immune cell expression) PD-L1 resulted associated to a good pathological response. On the contrary, high levels of intraepithelial CD4+ TILs were correlated with poor pathological response. FoxP3+ TILs, tumoral PD-L1 and CTLA-4 were not correlated to the treatment response. This meta-analysis indicated that high-density TILs might be predictive biomarkers of pathological response in patients that underwent NT for rectal cancer.
Sections du résumé
BACKGROUND
The main therapy for rectal cancer patients is neoadjuvant therapy (NT) followed by surgery. Immune biomarkers are emerging as potential predictors of the response to NT. We performed a meta-analysis to estimate their predictive significance.
METHODS
A systematic literature search of PubMed, Ovid MEDLINE and EMBASE databases was performed to identify eligible studies. Studies on patients with rectal cancer undergoing NT in which the predictive significance of at least one of the immunological markers of interest was assessed by immunohistochemistry (IHC) in pretreatment biopsies were included.
RESULTS
Seventeen studies reporting sufficient data met the inclusion criteria for meta-analysis. High levels of total CD3+, CD4+ and CD8+ tumor infiltrating lymphocytes (TILs), as well as stromal and intraepithelial CD8+ compartments, significantly predicted good pathological response to NT. Moreover, high levels of total (tumoral and immune cell expression) PD-L1 resulted associated to a good pathological response. On the contrary, high levels of intraepithelial CD4+ TILs were correlated with poor pathological response. FoxP3+ TILs, tumoral PD-L1 and CTLA-4 were not correlated to the treatment response.
CONCLUSION
This meta-analysis indicated that high-density TILs might be predictive biomarkers of pathological response in patients that underwent NT for rectal cancer.
Identifiants
pubmed: 37537787
doi: 10.1002/cam4.6423
pmc: PMC10523971
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17878-17890Investigateurs
Agostini Marco
(A)
Angriman Imerio
(A)
Bao Riccardo Quoc
(BR)
Bardini Romeo
(B)
Becherucci Giulia
(B)
Bergamo Francesca
(B)
Bordignon Giovanni
(B)
Brignola Stefano
(B)
Brolese Marco
(B)
Businello Gianluca
(B)
Buzzi Gianluca
(B)
Campi Michela
(C)
Candioli Salvatore
(C)
Capelli Giulia
(C)
Cataldo Ivana
(C)
Cavallin Francesco
(C)
Cipollari Chiara
(C)
Chiminazzo Valentina
(C)
Da Lio Corrado
(DL)
Dal Santo Luca
(DS)
D'Angelo Antonella
(D)
De Simoni Ottavia
(S)
Dei Tos Angelo Paolo
(DTA)
Di Camillo Barbara
(DC)
Di Cristofaro Loretta
(DC)
Facci Luca
(F)
Franzato Boris
(F)
Gavagna Laura
(G)
Godina Mario
(G)
Guerrieri Mario
(G)
Guerriero Silvio
(G)
Guzzardo Vincenza
(G)
Kotsafti Andromachi
(K)
Laurino Licia
(L)
Marchegiani Francesco
(M)
Maretto Isacco
(M)
Massani Marco
(M)
Merenda Roberto
(M)
Mondi Isabella
(M)
Negro Silvia
(N)
Ortenzi Monica
(O)
Parini Dario
(P)
Pilati Pierluigi
(P)
Pirozzolo Giovanni
(P)
Porzionato Andrea
(P)
Portale Giuseppe
(P)
Pozza Anna
(P)
Pozza Giulia
(P)
Prando Daniela
(P)
Pucciarelli Salvatore
(P)
Recordare Alfonso
(R)
Ricagna Fabio
(R)
Rivella Giorgio
(R)
Romiti Chiara
(R)
Ruffolo Cesare
(R)
Saadeh Luca
(S)
Salmaso Beatrice
(S)
Salmaso Roberta
(S)
Scapinello Antonio
(S)
Scognamiglio Federico
(S)
Spolverato Ylenia Camilla
(SY)
Stecca Tommaso
(S)
Tagliente Giovanni
(T)
Tomassi Monica
(T)
Tedeschi Umberto
(T)
Vignotto Chiara
(V)
Verdi Daunia
(V)
Zagonel Vittorina
(Z)
Zizzo Maurizio
(Z)
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Br J Cancer. 2014 Mar 18;110(6):1595-605
pubmed: 24504370
Oncotarget. 2017 Mar 21;8(12):19803-19813
pubmed: 28177891
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Am J Cancer Res. 2015 May 15;5(6):2064-74
pubmed: 26269765
Cancer Sci. 2018 Apr;109(4):966-979
pubmed: 29464828
Front Immunol. 2013 Dec 27;4:495
pubmed: 24416034
Clin Cancer Res. 2014 Apr 1;20(7):1891-9
pubmed: 24691640
Dis Colon Rectum. 2019 Apr;62(4):498-508
pubmed: 30844974
Lancet Oncol. 2011 Jun;12(6):575-82
pubmed: 21596621
J Natl Cancer Inst. 1996 Oct 16;88(20):1456-66
pubmed: 8841020
Br J Surg. 2020 Jan;107(1):131-139
pubmed: 31625143
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):629-39
pubmed: 27644910
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
Transl Res. 2015 Dec;166(6):721-732.e1
pubmed: 26209749
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Surg Oncol. 2021 Oct;28(11):6189-6198
pubmed: 33876358
Br J Surg. 2019 Sep;106(10):1381-1392
pubmed: 31197828
Gastroenterol Rep (Oxf). 2020 Jun 12;8(6):445-452
pubmed: 33442477
Cancer Treat Rev. 2020 Feb;83:101949
pubmed: 31869737
Immunol Rev. 2009 May;229(1):126-44
pubmed: 19426219
World J Surg Oncol. 2019 May 22;17(1):85
pubmed: 31118034
J Gastrointest Cancer. 2021 Jun;52(2):690-695
pubmed: 32643115
Cancer Immunol Res. 2018 Nov;6(11):1426-1441
pubmed: 30228206
Ann Surg. 2011 Jan;253(1):71-7
pubmed: 21135694
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Cancers (Basel). 2022 Jan 27;14(3):
pubmed: 35158905
J Natl Compr Canc Netw. 2020 Jul;18(7):806-815
pubmed: 32634771
Cancer Immunol Immunother. 2019 Feb;68(2):283-296
pubmed: 30448924
Biosci Rep. 2019 Mar 26;39(3):
pubmed: 30867256
Front Immunol. 2020 May 28;11:1052
pubmed: 32547556
Mod Pathol. 2021 Jan;34(1):171-183
pubmed: 32661298
Oncol Lett. 2019 Jan;17(1):1062-1070
pubmed: 30655866
Biomark Res. 2021 Jul 28;9(1):60
pubmed: 34321074
Oncotarget. 2017 Jun 7;8(43):75361-75371
pubmed: 29088871
J Cancer Res Clin Oncol. 2019 Apr;145(4):1043-1053
pubmed: 30874889
Cancer Med. 2023 Sep;12(17):17878-17890
pubmed: 37537787
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Cells. 2020 Sep 10;9(9):
pubmed: 32927784
Clin Cancer Res. 2020 Oct 1;26(19):5198-5207
pubmed: 32669377
Anticancer Res. 2014 Nov;34(11):6505-13
pubmed: 25368252
Eur J Cancer. 2018 Mar;91:11-20
pubmed: 29328976
Radiat Oncol. 2011 May 16;6:49
pubmed: 21575175
BJS Open. 2020 Apr;4(2):301-309
pubmed: 32026629
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1216-1224
pubmed: 29165286
Cancer Immunol Immunother. 2018 Apr;67(4):551-562
pubmed: 29270668
Ther Adv Med Oncol. 2022 Feb 21;14:17588359221077972
pubmed: 35222695
Br J Cancer. 2017 Aug 8;117(4):451-460
pubmed: 28704840